Definition
Transforming growth factor-beta 2 (TGF-β2) is a secreted protein belonging to the transforming growth factor-beta (TGF-β) superfamily that functions as an exercise-induced signaling molecule, primarily characterized as an adipokine released from adipose tissue PMID 35304603PMID 39852400.
Biological function
- Metabolic Regulation: TGF-β2 plays a central role in regulating glucose and fatty acid metabolism PMID 39852400PMID 35304603. It increases free fatty acid (FFA) uptake and oxidation while enhancing glucose uptake in skeletal muscle PMID 38786764PMID 41213606.
- Mitochondrial Optimization: It boosts mitochondrial function and respiratory capacity, contributing to cellular energy homeostasis PMID 39852400PMID 38786764.
- Tissue Crosstalk: It serves as a critical mediator of adipose–muscle tissue crosstalk, allowing fat cells to influence muscle metabolism PMID 39852400.
- Anti-inflammatory Activity: In adipose tissue, it is associated with a reduction in inflammation, particularly in the context of white adipose tissue (WAT) PMID 35304603PMID 41213606.
- Cellular Migration: It regulates myoblast migration through interactions with the extracellular matrix PMID 39854050.
Exerkine classification
- Lactate-Driven Secretion: TGF-β2 is classified as an exerkine because its expression and release from adipose tissue are sensitive to and stimulated by exercise-induced lactate produced by contracting skeletal muscle PMID 36633863PMID 39522716.
- Modal-Dependent Elevation: Research confirms that serum and plasma levels of TGF-β2 increase in response to different exercise modalities, including moderate-intensity training, high-intensity interval training (HIIT), and resistance training in both humans and mice PMID 39854050PMID 35304603.
- Systemic Transport: It operates through paracrine and endocrine signaling pathways to deliver metabolic signals from adipose tissue to target organs like skeletal muscle and brown adipose tissue (BAT) PMID 35304603PMID 39335489.
Therapeutic potential
- Metabolic Syndrome and Diabetes: TGF-β2 is identified as a promising therapeutic target for countering glucose intolerance, improving insulin sensitivity, and managing the pathophysiology of Type 2 Diabetes and metabolic syndrome PMID 38786764PMID 41213606.
- Obesity Management: Preclinical studies indicate that the administration of recombinant TGF-β2 can decrease fat mass and attenuate the inflammatory effects caused by a high-fat diet PMID 41213606.
- Sarcopenia: It is viewed as an "exercise-protective sensor" that maintains mitochondrial homeostasis to defend against age-related muscle loss and functional decline PMID 39852400.
- Knee Osteoarthritis (KOA): Although research is ongoing, it is recognized for its potential to promote chondrocyte synthesis and inhibit joint inflammation, offering a potential strategy for slowing KOA progression PMID 39854050.
- Pathological Paradox: Sources note that its therapeutic application must be context-specific, as abnormal TGF-β activation (such as during blood-brain barrier disruption) can occasionally lead to protein degradation and injurious effects PMID 36633863.
TGF-β2 has demonstrated therapeutic potential in several clinical areas, including wound healing, bone repair, immunosuppression in transplantology, and tissue regeneration, though its role in cancer is complex and context-dependent. PMID 38964148PMID 8954178
TGF-β2 shows promise in wound healing and tissue repair through its ability to promote fibroblast proliferation, enhance extracellular matrix formation, and regulate angiogenesis. PMID 8954178PMID 12725873 These properties make it particularly relevant for clinical applications in wound management and tissue regeneration.
Bone formation and repair represent another therapeutic application, as TGF-β2 plays a crucial role in regulating bone growth and is especially abundant in skeletal tissues. PMID 25709154 The TGF-β family, including TGF-β2, is considered essential in controlling metabolic homeostasis in bone tissue and the fracture healing process. PMID 25709154
Immunosuppressive applications have been explored, particularly in transplantology. TGF-β2 exhibits potent immunosuppressive effects by inhibiting IL-1-dependent lymphocyte proliferation and blocking lymphocyte DNA synthesis. PMID 3129508PMID 2808692 Both TGF-β1 and TGF-β2 demonstrate identical immunosuppressive effects and can suppress autoimmune T cell function. PMID 2808692
However, the therapeutic application in oncology is complicated by TGF-β2's dual role. While it can suppress tumor formation by controlling cell proliferation, tumor cells can become resistant to its growth-inhibiting properties, and TGF-β may promote tumor progression in advanced stages. PMID 38964148 This has led to strategies targeting TGF-β signaling pathway members as therapeutic targets in cancer treatment. PMID 38964148
The clinical utility of TGF-β2 is supported by knockout studies showing that precise regulation of each TGF-β isoform is essential for survival, with mice deficient in TGF-β2 displaying remarkable developmental abnormalities, particularly in the cardiovascular system. PMID 38067167PMID 8954178
Evidence
PubMed and ClinicalTrials.gov, snapshot of February 2026. Counts are keyword-based and include every study that mentions TGF-β2. Compare across exerkines →
References 15
Primary literature cited in this profile. Each identifier opens the article on PubMed.